Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10637-023-01347-6.pdf
Reference27 articles.
1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al Management of Immune-Related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2018 Jun10;36(17):1714–1768. doi: https://doi.org/10.1200/JCO.2017.77.6385
2. Rajan A, Kim C, Heery CR, Guha U, Gulley JL (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers. Hum Vaccin Immunother 12(9):2219–2231. https://doi.org/10.1080/21645515.2016.1175694
3. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391. https://doi.org/10.1093/annonc/mdv383
4. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000 Jul) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70(1):327–334. https://doi.org/10.1016/s0003-4975(00)01595-2
5. Tomschik M, Hilger E, Rath J, Mayer EM, Fahrner M, Cetin H et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95(10):e1426–e1436. https://doi.org/10.1212/WNL.0000000000010209
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3